Information Provided By: 
Fly News Breaks for April 19, 2017
ALIOF, JNJ
Apr 19, 2017 | 07:30 EDT
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
News For JNJ;ALIOF From the Last 2 Days
JNJ
Apr 16, 2024 | 12:01 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
JNJ
Apr 16, 2024 | 11:49 EDT
H.C. Wainwright notes that Legend Biotech (LEGN) partner Janssen, a division of Johnson & Johnson (JNJ), reported Q1 aggregate revenues for Carvykti that implied a 1% quarter-over-quarter contraction following 5% quarter-over-quarter growth recorded from Q3 to Q4. However, the flat sales in Q were "not alarming to us" as the firm expects a return to growth, with substantial growth in the second half of 2024 compared to the first half, says the analyst, who reiterates a Buy rating and $87 price target on Legend shares.
JNJ
Apr 16, 2024 | 09:30 EDT
Says has financial flexibility to consider multiple types of transactions.
JNJ
Apr 16, 2024 | 08:58 EDT
JNJ
Apr 16, 2024 | 08:52 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Macatawa... To see the rest of the story go to thefly.com. See Story Here
JNJ
Apr 16, 2024 | 06:43 EDT
JNJ
Apr 16, 2024 | 06:25 EDT
JNJ
Apr 16, 2024 | 06:23 EDT
JNJ
Apr 16, 2024 | 06:20 EDT
Reports Q1 revenue $21.4B, consensus $21.4B. "Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline," said Joaquin Duato, Chairman and Chief Executive Officer. "Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse."
JNJ
Apr 15, 2024 | 12:57 EDT
Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $6.21... Johnson & Johnson (JNJ), consensus $2.47... Bank of America (BAC), consensus 72c... Morgan Stanley (MS), consensus $1.66... PNC Financial (PNC), consensus $3.02... BNY Mellon (BK), consensus $1.19.
JNJ
Apr 15, 2024 | 06:28 EDT
JNJ
Apr 15, 2024 | 06:08 EDT
